KDM1A and Miyoshi myopathy: We also assessed the synergy of CFZ with various LSD1 inhibitors (LSD1i) [51–55] and observed that the allosteric inhibitors, SP2509 and SP2577, showed high synergistic effects with all FDA-approved PIs, whereas the enzymatic inhibitors GSK2879552 and GSK-LSD1 did not exhibit such effects in MM cells, despite inducing cell cycle arrest and differentiation in AML cells [56–58].